Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

Novo Nordisk's oral GLP-1 pill achieved its main target in a late-stage diabetes study involving children and adolescents ...

A MAN who repeatedly told a doctor he feared he was suffering a life-threatening diabetes complication died just days later ...

Pemafibrate and Telmisartan are medications primarily used to manage cholesterol and blood pressure, respectively. The study ...

Novo Nordisk’s oral GLP-1 therapy significantly lowered blood sugar in children and adolescents with type 2 diabetes in a late-stage trial, marking the first study of this drug class in the age group.

Early data from first participating employer show that SmartRx can save organizations millions by bypassing traditional PBMs to deliver ...

Mark Prausnitz in his lab. “While I may be the focal point, it’s not a recognition of me as an individual. It’s a recognition ...

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

Nerve pain feels different, and common painkillers often don't work. Experts explain why neuropathic pain needs targeted ...

Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety ...

Novo Nordisk A/S NVO reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide ...